A review of clinical studies on aclacinomycin A--phase I and preliminary phase II evaluation of ACM.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D000917:Antibody Formation / Q000187:drug effects; D002648:Child; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007700:Kinetics; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D051379:Mice; D008875:Middle Aged; D009153:Mutagens; D009279:Naphthacenes / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D009369:Neoplasms / Q000188:drug therapy; D051381:Rats
D000903:Antibiotics, Antineoplastic; D009153:Mutagens; D009279:Naphthacenes